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doi.org/1Abstract G protein coupled receptors (GPCRs) constitute one of the major cell surface receptor
families which is extensively studied. Since their discovery our understanding of GPCRs has
signiﬁcantly evolved and they have been a subject of two major recognitions by Nobel Prizes
awarded to scientiﬁc works related to GPCRs. In this Letter to the Editor the 2012 Nobel Prize
in Chemistry awarded to two GPCR experts, Professors Robert Lefkowitz and Brian Kobilka, is
used in the aim to more sensibilize the scientists and the decision-makers in the Arab world and
the Middle East for the interest that should been given to GPCRs. Moreover, the letter is supported
by a brief sight on GPCRs and the major advances regarding their chemistry, structure, signaling,
and pharmacology as well as their involvement in human diseases. Thus, I highly recommend the
scientiﬁc community in the Arab world to better consider GPCRs in the academic, medical, and
research programs and I hope that the 2012 Nobel Prize in Chemistry and this Letter to the Editor
will be the ultimate stimulating events.
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2 M.A. AyoubIn my Letter to the Editor, I would like to catch the atten-
tion of the scientists in the Arab world in both life and medical
ﬁelds on the importance of one of the major cell protein fam-
ilies named G protein-coupled receptors (GPCRs). Indeed,
GPCRs represent key cell membrane receptors involved in
our physiology and pathophysiology making them potential
pharmacological targets. The argument that I would like to
use is of course the recent 2012 Nobel Prize in Chemistry
awarded to Professors Robert Lefkowitz from the Duke Uni-
versity Medical Center and Brian Kobilka from the Stanford
University in the USA (The Nobel Prize in Chemistry, 2012).
Indeed, almost 20 years after the ﬁrst Nobel Prize in Medicine
or Physiology was awarded to Alfred G. Gilman and Martin
Rodbell in 1994 for their seminal discovery related to GPCRs
(The Nobel Prize in Physiology or Medicine, 1994) their
GPCRs won the 2012 Nobel Prize in Chemistry for the pioneer
works undertaken on GPCR structure, signaling and pharma-
cology. Consequently, I hope that this brief insight will make
the scientists in the world, and particularly those who are oper-
ating in the different countries of the Arab world, more sensi-
tive to GPCRs and their related research ﬁelds. Indeed, the
recent advances in GPCRs should have a real impact on the
Arab researchers and academicians hopefully encouraging
them to have another view particularly in terms of teaching,
studying, and investigating GPCRs. In my opinion, the aca-
demic programs proposed to students in different colleges
and departments (medicine, pharmacy, biology, and chemis-
try) are to some extent poor with respect to GPCRs and their
biology and chemistry. Similarly, the research projects tend to
ignore this super family of cell surface receptors. This seems to
be true for the projects which are related to cancer, diabetes
and other major disorders in the endocrine and nervous sys-
tems given that some of these disorders including diabetes
are reported to present an increasing incidence in this region
of the world (The International Diabetes Federation Diabetes
Atlas, 2011). Thus, the research projects on GPCRs may cover
the genetic/genomic/clinical investigations and experimental as
well as molecular pharmacology. In addition, the fundamental
research on GPCRs may constitute a promising ﬁeld of re-
search which consists of structure–function and biochemical
studies using new innovative technologies that could be trans-
ferred through international collaborations.
The importance of GPCRs resides in the fact that they
constitute the largest cell surface protein family (1–3% of the
human genes and 900 receptors identiﬁed) involved in 80%
of signaling through the plasma membrane of our cells.
Moreover, GPCRs are known to regulate the major biological
functions such as neurotransmission, secretion, contraction,
cell growth and migration (Bockaert and Pin, 1999; Fredriksson
et al., 2003). This diversity of GPCR action is in fact linked to
the diversity of stimuli known to activate these receptors
including light, odorants, nucleotides, peptides, neurotransmit-
ters, and protein hormones (Bockaert and Pin, 1999;
Fredriksson et al., 2003). Interestingly, the importance of
GPCRs is illustrated by their well established implication in
diverse pathologies such as neurological disorders, cardiovas-
cular diseases, cancer, allergies, and diabetes (Insel et al.,
2007; Spiegel and Lee, 2004). Also GPCRs have been reported
to constitute an important molecular constituent used by
certain pathogens during the infection process (Coureuil
et al., 2010). Thus, because of their central role in pathology
GPCRs present a particular interest for the pharmaceuticalPlease cite this article in press as: Ayoub, M.A. The Nobel Prize in Chemistr
of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2013.08.020farms since they are the target of about 50% of the drugs used
nowadays in medicine (Esbenshade, 2006).
Since the discovery of the key element involved in GPCR
function and signaling (i.e. G proteins and cAMP) in 70–80’s
(Rodbell et al., 1969), which led the Nobel Prize in Medicine
or Physiology to be shared between Alfred G. Gilman and
Martin Rodbell in 1994 (The Nobel Prize in Physiology or
Medicine, 1994), and for the cloning of the ﬁrst GPCR which
is b-adrenergic receptor in 1986 (Dixon et al., 1986), GPCRs
continue to be the center of intense investigation and research
in both academic and pharmaceutical laboratories. As a result,
considerable progresses have been reached such as the crystal
structure of rhodopsin in 2000 (Palczewski et al., 2000) and
later on that of various GPCRs (bound or not with their selec-
tive ligands and G proteins) obtained by Kobilka’s group
(Granier and Kobilka, 2012), and many new intriguing
concepts have emerged such as oligomerization, G protein-
independent signaling, and biased signaling (Eglen et al.,
2007). For instance, GPCR oligomerization constitutes one
of the major revolutionary advances of the last decade since
it is now evident that these transmembrane proteins can form
homo- (between identical receptor proteins) and heteromer
(between different receptor proteins) complexes with speciﬁc
pharmacological, biological, and biochemical properties (Devi,
2001). Interestingly, such speciﬁc properties might open new
therapeutic perspectives to treat human diseases such as
neurodegenerative and neuropsychiatric diseases since GPCR
heteromers represent potential drug targets (Franco, 2009).
Consequently, the research on GPCR oligomers, especially
heteromers, constitutes a very attractive ﬁeld of research as
illustrated by the increasing number of scientiﬁc publications
on GPCR oligomerization. Moreover, for a long time GPCRs
were named to have been thought to trigger cell signaling only
via the interaction with and activation of another major cell
protein family, the heterotrimeric G proteins. However, many
recent studies including those reported by Professor Robert
Lefkowitz have shown that GPCRs also mediate signaling
via diverse pathways involving various intracellular proteins
independently on the heterortimeric G proteins (i.e. arrestins,
src, and tyrosine kinase) (Lefkowitz and Shenoy, 2005). This
diversity and multiplicity in GPCR signaling further demon-
strate the complexity of this family of receptors which opens
more promising possibilities for research and investigation.
Recently, the concept of biased signaling mostly supported
by the seminal works from Lefkowitz’s laboratory has emerged
in the GPCR ﬁeld (Whalen et al., 2011; Rajagopal et al., 2010).
The biased signaling is in fact tightly linked to the multiple
signaling of GPCRs (G protein-dependent and G protein-
independent) and it is deﬁned as the property that some
ligands/drugs (agonists or antagonists) may have which con-
sists to activate one speciﬁc signaling pathway and not others
via the activation and/or the stabilization of one speciﬁc con-
formation or state of the targeted receptor. Understanding
the biased signaling of GPCRs and their drugs will certainly
help the pharmaceutical laboratories to develop new genera-
tion of drugs that are more speciﬁc, selective, and efﬁcient with
fewer side effects. All these ﬁndings illustrate the diversity and
the complexity of GPCR function emphasizing the importance
of updating our knowledge on GPCRs in fundamental,
applied, and clinical research and academic programs. In
addition, all the recent advances in GPCRs are now pushing
the pharmaceutical farms to revise their drug discovery andy 2012, G protein-coupled receptors, rightly rewarded. Arabian Journal
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objective to improve human health.
Finally, I believe that the 2012 Nobel Prize in Chemistry
constitutes a ‘‘second recognition’’ of the GPCR ﬁeld which
will certainly open a new area in research on this family of
drug targets. Therefore, patricians, academicians and research-
ers in the Arab world should take part in this new area for the
beneﬁt of the local and worldwide populations.Acknowledgments
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